FIELD: chemistry.
SUBSTANCE: present invention relates to novel inhibitors of S-nitrosoglutathione reductase (GSNOR) of formula I, wherein X is selected from a group consisting of O and S; Y is selected from a group consisting of O and S; Z is selected from a group consisting of Z1, Z2, Z3 and Z4, wherein Z1 denotes , Z2 denotes , Z3 denotes and Z4 denotes , with the proviso that Z is only Z4, when at least one of X or Y is S; R1 is selected from a group consisting of hydrogen, (C1-C6) alkyl, (C1-C6) haloalkyl; R2 is selected from a group consisting of hydrogen, halogen; R3 is selected from a group consisting of hydrogen, halogen; R4 is selected from a group consisting of tetrazole, oxadiazolone, thiadiazolone, methylsulphonylcarbamoyl and N-hydroxycarbamoyl; and R5 is selected from a group consisting of carboxy, tetrazole or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions containing such inhibitors of GSNOR, and their use.
EFFECT: providing pharmaceutical compositions.
16 cl, 24 ex
Title | Year | Author | Number |
---|---|---|---|
BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | 2016 |
|
RU2738232C2 |
BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
NOVEL HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2019 |
|
RU2769507C1 |
ANTIFIBROUS PYRIDINONES | 2015 |
|
RU2692485C2 |
COMPOUNDS WITH CONDENSED RINGS | 2019 |
|
RU2783414C2 |
ESTROGEN RECEPTOR MODULATORS | 2017 |
|
RU2738646C2 |
FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
Authors
Dates
2016-06-10—Published
2011-02-10—Filed